C07D 241/54
Nitrogen atoms
C07D241/54 (Nitrogen atoms) appears on 28 US grants and 31 published applications in this corpus.
Search patents in C07D- Granted patents
- 28
- Published applications
- 31
- Assignees
- 22
- Inventors
- 76
- Latest grant
- 4 Oct 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 1 |
| 2002 | 1 | 0 |
| 2003 | 2 | 4 |
| 2004 | 2 | 0 |
| 2005 | 2 | 2 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 1 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 3 |
| 2013 | 2 | 2 |
| 2014 | 3 | 2 |
| 2015 | 3 | 5 |
| 2016 | 1 | 1 |
| 2017 | 0 | 1 |
| 2018 | 1 | 1 |
| 2019 | 0 | 0 |
| 2020 | 1 | 1 |
| 2021 | 0 | 1 |
| 2022 | 1 | 0 |
| 2023 | 0 | 2 |
| 2024 | 0 | 2 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Heterocyclic compounds for the inhibition of PASK4 Oct 2022US 11,459,307 B2BioEnergenix LLC
- Heterocyclic compounds for the inhibition of PASK22 Sep 2020US 10,781,185 B2BioEnergenix LLC
- Heterocyclic compounds for the inhibition of PASK16 Jan 2018US 9,868,708 B2BioEnergenix LLC
- Substituted pyrazines and a process for producing the same24 May 2016US 9,346,767 B2Jnc Corporation
- Heterocyclic compounds for the inhibition of PASK24 Nov 2015US 9,193,693 B2BioEnergenix LLC
- Inhibitors of spns2 and uses thereof16 Jul 2026US 2026/0200896 A1New York University
- Bisdiaminophenyl compound, crosslinking agent, composition, and molded article14 Mar 2024US 2024/0084102 A1Daikin Industries, Ltd.
- Crac channel inhibitor compositions22 Feb 2024US 2024/0058332 A1Calcimedica, Inc.
- Modulators of cystic fibrosis transmembrane conductance regulator23 Nov 2023US 2023/0373974 A1Vertex Pharmaceuticals Incorporated
- Culture medium for laryngeal cancer epithelial cells, culture method, and application thereof6 Jul 2023US 2023/0212523 A1Cas (Hefei) Institute of Technology Innovation
Most cited
By later US patents
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases232US 6,180,632 B2Aventis Pharmaceuticals Products Inc. · 2001
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases219US 6,482,834 B2Aventis Pharmaceuticals Inc. · 2002
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases207US 6,245,760 B1Aventis Pharmaceuticals Products Inc. · 2001
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases189US 6,528,526 B1Aventis Pharmaceuticals Inc. · 2003
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56.sup.lck tyrosine kinases188US 6,159,978 AAventis Pharmaceuticals Product, Inc. · 2000